This exercise endeavors to bring Policy makers in India
• Ministry of Health
• Ministry of Finance
• Ministry of Biotechnology
• State Health Ministries
• Niti Aayog
• ICMR (Indian Council of Medical Research)
• NICPR (National Institute of Cancer Prevention & Research)
• NPPA (National Pharmaceutical Pricing Authority)
• DCGI (Drug Controller General of India)
• MCI (Medical Council of India)
Together with various stakeholders comprising
• OPPI (Organisation of Pharmaceutical Producers of India)
• IDMA (Indian Drug Manufacturers’ Association)
• Biotech Industry
• Molecular Diagnostic Industry
• Technical infrastructure corporates like Radiation Equipment Manufacturers, Innovators,
• Proprietors and Management of Tertiary Care & stand alone Cancer Hospitals
• Oncology Opinion Makers
• Insurance & Banking industry
• Print and Electronic Media
• Consumer Patient Advocates
A glimpse of topics to be discussed threadbare are as follows
1. Patent rights for Health Care Products in India – Do they require tweaking?
2. Orphan Drugs and their relevance in Cancer Care India.
3. Biosimilars in Oncology – the way forward in India.
4. Taxation for Oncology products in India needs revisiting.
5. Pricing for Cancer Care in India – Practicality & Affordability.
6. Health Insurance for Cancer Treatment – products available, evolution.
7. Improving Access to Cancer Diagnostics: Entrepreneurial Strategies
8. Impetus to Research & Development in India.
9. Government Policies in Affordable Cancer Care: “Past, Present and Future – a 20 year overview”
10. Enabling effective tertiary healthcare system in India – A much needed reform
11. Family Ecosystem in cancer care